产品说明书
Roquinimex
 |
同义名 : | 罗喹美克 ;Linomide;ABR212616;Linomide. US brand name: Linomide.;Roquinimex, FCF-89;PNU 212616;LS 2616;FCF89 |
| CAS号 : | 84088-42-6 | |
| 货号 : | A809531 | |
| 分子式 : | C18H16N2O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 308.331 | |
| MDL号 : | MFCD00866331 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 85 mg/mL(275.68 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant that enhances NK cell activity and macrophage cytotoxicity, inhibits angiogenesis, and reduces TNF alpha secretion. Its IC50 value for TNF alpha is noteworthy. Prophylactic administration of roquinimex to DSS-treated mice significantly diminishes clinical signs of colitis, MDS, and CH-reduction. Additionally, in roquinimex-treated animals, MPO activity is notably reduced by over 50% compared to DSS control mice. Therapeutic administration of roquinimex in DSS-treated mice also significantly hampers MDS, CH-reduction, and MPO activity [2]. Linomide, a synthetic immunomodulator, at effective concentrations in vivo , reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing mononuclear cells (MNC) from MS patients' blood when analyzed in vitro. Compared to dexamethasone, Linomide upregulates levels of blood MNC expressing mRNA of TGF-beta after culture in the presence of MBP [3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.24mL 0.65mL 0.32mL |
16.22mL 3.24mL 1.62mL |
32.43mL 6.49mL 3.24mL |
| 参考文献 |
|---|